Contributors

Autor: Rick Adler, Famke Aeffner, Laura E. Armstrong, Dmitri Artemov, Adam D. Aulbach, Bindu M. Bennet, Eric A. Blomme, Brad Bolon, Christopher J. Bowman, Molly Boyle, Alys Bradley, Dino Bradley, Danielle Brown, Pierre R. Bushel, Ellen Cannady, Mark F. Cesta, Curtis Chan, Jennifer A. Chilton, Peter J.M. Clements, Torrie A. Crabbs, Myrtle A. Davis, Sandy Eldridge, Daniela Ennulat, Jeffrey Everitt, Isabel Figueroa, James D. Fikes, Thomas Forest, Catherine A. Foss, John R. Foster, Kathleen Gabrielson, Shayne C. Gad, Kapil Gadkar, Jinping Gan, David Garcia-Tapia, Frank J. Geoly, Wendy G. Halpern, Jerry F. Hardisty, Wanda M. Haschek, Kathleen Marie Heinz-Taheny, Kristi Helke, Lauren E. Himmel, Mark J. Hoenerhoff, Jennifer L. Ingram–Ross, Armando R. Irizarry Rovira, Evan B. Janovitz, Kishore Katyayan, Charlotte M. Keenan, Angela King-Herbert, Steven T. Laing, Lois D. Lehman-McKeeman, Na Li, Calvert Louden, Claire Lyons, Kevin McDorman, Elizabeth McInnes, Lyn Miller Wancket, Sheroy Minocherhomji, Sébastien Monette, James Morrison, Vasanthi Mowat, Sydney Mukaratirwa, Keith Nelson, Arun R. Pandiri, Tracey Papenfuss, Nita Patel, Daniel J. Patrick, Shari A. Price, Deepa B. Rao, James T. Raymond, Jennifer Rojko, Colin G. Rousseaux, Sara F. Santagostino, Aaron Sargeant, Christina Satterwhite, A. Eric Schultze, Vanessa Schumacher, Cheryl Scudamore, Keith R. Shockley, Bhanu P. Singh, David M. Stresser, Polina Sysa-Shah, Debra A. Tokarz, Terry Van Vleet, Matthew A. Wallig, Jin Wang, Cynthia J. Willson, Kristin Lewis Wilson, Christopher T. Winkelmann, Jeffrey C. Wolf, Charles Wood, Daniela Bumbaca Yadav, Mark Zarella

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3831ed61c4599a4d47034bfb7e19d99
https://doi.org/10.1016/b978-0-12-821044-4.01002-5

Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate)

Autor: Szczepan W, Baran, Paul C, Brown, Andreas R, Baudy, Suzanne C, Fitzpatrick, Christopher, Frantz, Aaron, Fullerton, Jinping, Gan, Rhiannon N, Hardwick, Kathleen M, Hillgren, Anna K, Kopec, Jennifer L, Liras, Donna L, Mendrick, Ryan, Nagao, William R, Proctor, Diane, Ramsden, Alexandre J S, Ribeiro, David, Stresser, Kyung E, Sung, Radhakrishna, Sura, Kazuhiro, Tetsuka, Lindsay, Tomlinson, Terry, Van Vleet, Matthew P, Wagoner, Qin, Wang, Sevim Yildiz, Arslan, Gorm, Yoder, Jason E, Ekert

Publikováno v: ALTEX.

Complex in vitro models (CIVM) offer the potential to improve pharmaceutical clinical drug attrition due to safety and/ or efficacy concerns. For this technology to have an impact, the establishment of robust characterization and qualifi­cation plan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::991b82190055f9a932fb29fb1692bafd
https://doi.org/10.14573/altex.2112203

d-α-tocopheryl polyethylene glycol 1000 succinate-containing vehicles provide no detectable chemoprotection from oxidative damage

Autor: Marc H. Davies, Roderick T. Bunch, Robert W. Lange, Bethany R. Baumgart, Michael Donegan, Damir Simic, Theodora W. Salcedo, Kimberley A. Lentz, Terry Van Vleet, Thomas P. Sanderson

Publikováno v: Journal of Applied Toxicology. 35:791-798

The objective of this study was to evaluate potential protective effects of vehicles containing d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), which may impact nonclinical safety assessments of oxidative processes. This was achieved by ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::635f7d6cb8d0ab56a34aafd029e327fc
https://doi.org/10.1002/jat.3072

MicroRNA changes associated with atypical CYP1A1 inducer BMS-764459

Autor: Aiqing He, Terry Van Vleet, Thomas P. Sanderson, R. Todd Bunch, Damir Simic, Emily Haines, Catherine Euler, W. Mike Peden

Publikováno v: Toxicology. 311:169-177

The corticotrophin releasing factor (CRF) receptor I antagonist, BMS-764459 (evaluated as a potential treatment of affective disorders), was orally dosed to female Sprague-Dawley rats once daily for 2 weeks (vehicle control or 175mg/kg/day). To inves

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d045bfb4979af101913f448373e86d06
https://doi.org/10.1016/j.tox.2013.06.006

Subchronic Urinary Bladder Effects of Muraglitazar in Male Rats1

Autor: Samuel M. Cohen, James Mitroka, Martin Cano, Mark A. Dominick, M. Randy White, C. Robbie Waites, Lora L. Arnold, Terry Van Vleet, Thomas P. Sanderson, Beth E. Schilling

Publikováno v: Toxicological Sciences. 96:58-71

Muraglitazar, a PPARa/g dual agonist, was dosed orally to rats once daily for 13 weeks to evaluate urinary and urothelial changes of potential relevance to urinary bladder tumorigenesis. Groups of 17 young or aged rats per sex were fed a normal or 1%

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e537d87061d08b00aeab171e37a4f68
https://doi.org/10.1093/toxsci/kfl176